Table 2.
Baseline Characteristics by Cancer Event Status—Strategic Timing of Antiretroviral Treatment (START) Trial
| Characteristic | No Cancer | Infection-Related Cancer | Infection-Unrelated Cancer |
|---|---|---|---|
| No. of participants | 4632 | 29 | 24 |
| Demographics | |||
| Age, y, median (IQR) | 36 (29–44) | 44 (31–48) | 51 (36–59) |
| Sex, % female | 26.9 | 10.3 | 25.0 |
| Race, % | |||
| Asian | 8.4 | 0.0 | 4.2 |
| Black | 30.3 | 13.8 | 16.7 |
| Latino/Hispanic | 13.7 | 10.3 | 4.2 |
| White | 44.2 | 75.9 | 75.0 |
| Other | 3.5 | 0.0 | 0.0 |
| Region, % | |||
| High income | 45.8 | 51.7 | 79.2 |
| Low to middle income | 54.2 | 48.3 | 20.8 |
| HIV history, % | |||
| Likely mode of HIV infection | |||
| Sexual contact with person of same sex | 55.1 | 79.3 | 54.2 |
| Sexual contact with person of opposite sex | 38.3 | 20.7 | 37.5 |
| Injection drug use | 1.4 | 0.0 | 4.2 |
| Blood products/other/unknown | 5.3 | 0.0 | 4.2 |
| Time participant known to be HIV infected, y, median (IQR) | 1.0 (0.4–3.0) | 0.7 (0.3–3.4) | 2.3 (0.6–4.4) |
| Laboratory results | |||
| CD4 counta, cells/µL, median (IQR) | 651 (584–764) | 671 (587–770) | 638 (562–759) |
| CD4:CD8 ratio, median (IQR) | 0.66 (0.48–0.90) | 0.57 (0.42–0.73) | 0.56 (0.38–0.75) |
| CD8 count, cells/µL, median (IQR) | 1040 (774–1400) | 1152 (986–1892) | 1150 (821–1499) |
| HIV RNA, log10 copies/mL, median (IQR) | 4.1 (3.5–4.6) | 4.6 (4.0–5.0) | 4.2 (3.9–4.5) |
| Highest HIV RNAb, log10copies/mL, median (IQR) | 4.3 (3.7–4.8) | 4.8 (4.1–5.3) | 4.5 (4.2–5.0) |
| Medical history, % | |||
| Hepatitis B | 2.8 | 0.0 | 0.0 |
| Hepatitis C | 3.7 | 0.0 | 12.5 |
| Prior non-AIDS cancer | 0.4 | 0.0 | 4.2 |
| Current smoker | 31.8 | 44.8 | 41.7 |
| Alcoholism or other substance dependence | 3.3 | 0.0 | 4.2 |
| Body mass index, kg/m2, median (IQR) | 24.5 (22.1–27.9) | 25.9 (22.8–29.6) | 25.4 (22.3–27.2) |
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range.
a Average of screening and baseline values.
b Documented in participant record.